Budesonide (micronized) 0.25mg/2mL, 0.5mg/2mL, 1mg/2mL; susp for inhalation. Pulmicort Respules is supplied in sealed aluminum foil envelopes containing one plastic strip of five single-dose Respules ...

Budesonide (Budecort Respules (1 mg)) is a corticosteroid, prescribed for inflammatory bowel disease, asthma, and also for breathing trouble. Budesonide is indicated for: 1. Treatment of Mild to ...

What is budesonide for nebulization used for? Budesonide for nebulization is commonly used as a controller medicine for asthma, a long-term lung disease involving narrow and inflamed airways, which ...

Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, announced the launch of the generic equivalent to Pulmicort Respules (budesonide inhalation suspension), 1 mg/2 ml, in the ...

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL from the United States Food and Drug ...

Citing IMS Health data, Cipla said Pulmicort Respules and generic equivalents had US sales of approximately USD 825 million for the 12 months to September 2017. Drug major Cipla today said it has ...

Budesonide (Budecort 0.5mg Respules 2ml) is a corticosteroid, prescribed for inflammatory bowel disease, asthma, and also for breathing trouble. Budesonide is indicated for: 1. Treatment of Mild to ...

NEW YORK (Reuters) - A U.S. federal judge ruled late on Friday that AstraZeneca PLC's (AZN.L) patent on its Pulmicort Repsules treatment for asthma was invalid, opening up the market to a second, ...

AstraZeneca today announced that the US District Court for the District of New Jersey ruled US Patent No. 7,524,834 ("the '834 patent"), protecting PULMICORT RESPULES in the US, is invalid.

Budesonide (micronized) 0.25mg/2mL, 0.5mg/2mL, 1mg/2mL; susp for inhalation. Pulmicort Respules is supplied in sealed aluminum foil envelopes containing one plastic strip of five single-dose Respules ...

Drug major Cipla today said it has received final approval from the US health regulator for a suspension product used for treatment of asthma. In a BSE filing today, Cipla said "it has received final ...